DNTH logo

DNTH
Dianthus Therapeutics Inc

1,248
Mkt Cap
$4.75B
Volume
499,658.00
52W High
$96.50
52W Low
$16.64
PE Ratio
-21.19
DNTH Fundamentals
Price
$83.67
Prev Close
$87.16
Open
$87.12
50D MA
$75.84
Beta
1.08
Avg. Volume
1.58M
EPS (Annual)
-$4.20
P/B
7.64
Rev/Employee
$22,130.44
$1,188.52
Loading...
Loading...
News
all
press releases
Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000
Key Points8,224 shares (~$739,000) of common stock were sold on April 9, 2026, at a weighted average price of around $89.84 per share...
Nasdaq News: Markets·9d ago
News Placeholder
More News
News Placeholder
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Recommendation of "Buy" from Analysts
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) has been assigned a consensus recommendation of "Buy" from the fourteen analysts that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, eleven have given a buy recomm...
MarketBeat·13d ago
News Placeholder
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 1-Year High - Should You Buy?
Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 12-Month High - Still a Buy...
MarketBeat·14d ago
News Placeholder
SG Americas Securities LLC Invests $765,000 in Dianthus Therapeutics, Inc. $DNTH
SG Americas Securities LLC purchased a new stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities...
MarketBeat·17d ago
News Placeholder
Dianthus Therapeutics (NASDAQ:DNTH) EVP Ryan Savitz Sells 8,224 Shares
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) EVP Ryan Savitz sold 8,224 shares of the firm's stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an...
MarketBeat·18d ago
News Placeholder
Dianthus Therapeutics (NASDAQ:DNTH) Upgraded by Wolfe Research to "Strong-Buy" Rating
Wolfe Research upgraded shares of Dianthus Therapeutics to a "strong-buy" rating in a research note on Wednesday...
MarketBeat·18d ago
News Placeholder
Wolfe Research Begins Coverage on Dianthus Therapeutics (NASDAQ:DNTH)
Wolfe Research initiated coverage on shares of Dianthus Therapeutics in a research note on Thursday. They set an "outperform" rating and a $98.00 target price for the company...
MarketBeat·19d ago
News Placeholder
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 12-Month High - Time to Buy?
Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week High - What's Next...
MarketBeat·20d ago
News Placeholder
Dianthus Therapeutics CFO Sells $9.5 Million in Stock
Key Points114,367 shares were sold for a transaction value of approximately $9.49 million on March 31, 2026...
Nasdaq News: Markets·22d ago
News Placeholder
JPMorgan Chase & Co. Has $2.68 Million Stock Position in Dianthus Therapeutics, Inc. $DNTH
JPMorgan Chase & Co. lifted its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 626.4% during the third quarter, according to the company in its most recent filing with...
MarketBeat·22d ago
<
1
2
...
>

Latest DNTH News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.